HIGHLIGHTS
SUMMARY
Chronic lymphocytic leukemia (CLL), high-risk, TP53, definition, BTK - Bruton`s tyrosine kinase, BCL2 (B-cell lymphoma 2), COVID - 19, risk factor CITATION Edelmann J, Malcikova J and Riches JC Opinion: What defines high-risk CLL in the post-chemoimmunotherapy era? While other biomarkers such as unmutated IGHV, del(11q), high ZAP70 expression and high CD38 expression were associated with inferior prognosis, TP53 deficiency by mutation and/or del (17p) remained the only biomarker that clearly guided treatment decisions. The emergence of targeted compounds has rendered chemoimmunotherapy virtually obsolete for CLL treatment, with it . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.